Author

Noriaki Kaneda

Observed name: 金田倫明

Institutions: Kyoto Research Park, Maruho (Japan)

Observed institutions: Kyushu Institute of Technology, Kyoto Research Park, Maruho (Japan)

ORCID: 0009-0008-4265-8827

Observed ORCID: 0009-0008-4265-8827

OpenAlex ID: A5102076500

Prediction of Percutaneous Absorption in Human Using Three-Dimensional Human Cultured Epidermis LabCyte EPI-MODEL

2012 · Tomohiro Hikima, Noriaki Kaneda, et al. · Biological and Pharmaceutical Bulletin · 19

Pharmacological profiles and clinical findings of nemolizumab as treatment for pruritus associated with atopic dermatitis

2023 · Noriaki Kaneda · Folia Pharmacologica Japonica · 3

Machine-Learning-Based Prediction of Long-Term Efficacy of Nemolizumab: Post Hoc Analysis of Pooled Data from Two Phase III Clinical Trials

2026 · Makoto Kawashima, Tomoya Maeda, et al. · Dermatology and Therapy

Corrigendum to ‘Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab’ JID Innovations, Volume 6, Issue 3, May 2026, 100457

2026 · Saeko Nakajima, Hajime Iizuka, et al. · JID Innovations

Plasma proteomic profiles of patients with atopic dermatitis with moderate-to-severe pruritus treated with a single dose of nemolizumab

2026 · Saeko Nakajima, Hajime Iizuka, et al. · JID Innovations

ヒト3次元培養表皮モデルLabCyte EPI-MODELを用いた薬物透過性の評価

2008 · 松尾恭平, 金田倫明, et al. · 化学工学会　研究発表講演要旨集化学工学会第73年会

Works count: 6

Citation count: 22

H-index: 2

I10-index: 1